Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
for Ovarian Cancer
Drug: Bevacizumab
28 locations incl. La Jolla
Sponsor: Daiichi Sankyo
Sex: Female·Age: 18+
Code: NCT06819007·Phase 3·Recruiting